I have just returned from a WW2 pilgrimage of all things Normandy landings, alongside watching the award-winning 2001 "Band of Brothers" drama - telling the true story of how Easy Company (US Army 101st Airborne Division) overcame immense danger to ultimately prove victorious in helping to liberate Europe between 1942-45.
Similarly, although to a much lesser extent, I feel Belluscura - a developer of best-in-class portable oxygen concentrators (POCs) used to treat respiratory conditions like COPD - has faced and overcome a series of significant challenges over the past 3 years.
The latest being President Trump slapping 54% trade tariffs on China, with Beijing imposing 34% retaliatory tariffs on US imports. Worst still, both sides don't yet appear to be backing down, so a prolonged standoff may ensue.
No wonder therefore, like many other international corporations, Belluscura - who manufactures a large proportion its US-bound POCs, components and sub-assemblies in China via its partner Innomax - announced this morning that it was withdrawing FY25 guidance. Here, the Board had previously anticipated FY25 revenues of $12.7m and EBITDA to turn positive in Q4'25 on an annualised revenue run rate of $16m.
The good news is that the management team are battle hardened veterans of this type of difficulty, and should be able to find another workable solution to the latest problem. Plus, after raising £4.7m (gross) at 2p/share in Feb'25, the business should also have sufficient capital to ride out the current storm.
Follow News & Updates from Belluscura: